fashion -WSS

fashion

author：Wikipedia 2025-09-29 22:36:36 - browse：66892

FDA's Peter Marks talks with STAT's Adam Feuerstein — Peter Marks, the FDA's top regulator of gene therapies (right), speaks with STAT's Adam Feuerstein in San Francisco. Sarah Gonzalez/Peopletography for STAT

SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies, seems very comfortable with granting some form of full approval to Elevidys, the Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy, based on his comments to me on Monday night during our “fireside chat” at a STAT event.

To be clear, Marks declined to comment specifically about the ongoing FDA review of Elevidys. I tried. However, Marks described a “hypothetical case” in the context of my Sarepta questions that clearly suggested the failure of an Elevidys confirmatory study in October didn’t bother him all that much.

“Hypothetically, if you had a product that used an aggregate scale and all of the components of that aggregate scale looked pretty good, or nearly all of them look pretty good, but the aggregate, for various reasons, didn’t come out perfectly. We approved products based on that,” Marks told me.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Anavex keeps shifting the goalposts in its clinical trials

WSS

The dental labor crisis is a moment of opportunity

Friends ask where James Watson's attitudes about race came from

For Cytokinetics, FDA rejection of heart drug would help, not hinder

How to use technology to prevent future drug shortages

Wegovy’s successful heart trial raises vital question about weight loss

Vaccine advisory panel ACIP left half staffed by HHS

focus

fashion

focus

Affirmative action in medical school literally saved lives

Wegovy’s successful heart trial raises vital question about weight loss

Virginia high school admissions case could be legal follow

Methadone doses haven’t kept up in the age of fentanyl

Continuity nursing helped my family in our darkest PICU moments

Drastic changes should bring profitability, startup health insurers say

Cancer drug shortages should be causing more outrage

Why did Pfizer dish out millions for a Super Bowl ad?

Activists slam private health insurers over coverage restrictions

Emergent cuts jobs, executive role in business shake

focus

Wegovy trial has doctors encouraged over new possibilities

What should King Charles tell the public about his cancer?

NIH trials fail to test meaningful long Covid therapies, experts say

PhRMA lawsuit over Medicare drug price negotiation tossed

In same hospitals, Black patients receive fewer opioids than white patients

Biden report: The neurospychology of memory and aging

focus

leisure time

hotspot

entertainment